3/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder

恐慌症中的 3/3 暴露 D-环丝氨酸增强剂和遗传调节剂

基本信息

  • 批准号:
    7795799
  • 负责人:
  • 金额:
    $ 23.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-04-24 至 2013-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This is a 3-center (PIs: Drs. Otto, Pollack, Tolin) collaborative R01. In this application, we propose to further validate and expand upon one of the apparent striking successes of translational research. Specifically, basic research on the neural circuitry underlying fear extinction led to the examination of d-cycloserine, a partial agonist at the NMDA receptor in the amygdala, as an agent capable of enhancing extinction learning (Davis et al., 2006a; Davis et al., 2006b). Following successful validation of this strategy in the animal laboratory, Ressler et al. (2004) showed that single doses of d-cycloserine (DCS) could enhance extinction in a human exposure paradigm for height phobic adults. This exciting initial finding was replicated by our research team for the treatment of social anxiety disorder in outpatients (Hofmann et al., 2006), and we also have completed a pilot study indicating similar benefits for the treatment of other anxiety disorders. As discussed by Anderson and Insel (2006), these findings have the potential to foster significant advances in the treatment of anxiety disorders. The present study represents the further application of DCS for augmenting the effects of exposure- based cognitive-behavior therapy (CBT), now applied to the treatment of panic disorder with or without agoraphobia. In this application we propose a double-blind randomized controlled trial, conducted at three treatment sites, to compare the relative benefit of augmenting exposure-based CBT with DCS as compared to placebo for patients with panic disorder. In addition, by studying variability at specific gene sites as a predictor of treatment response, particularly for the effects of DCS augmentation, we seek to identify which patients may be particularly responsive to this form of brief, combined treatment. This study capitalizes on the recent successes in translational research to investigate the benefits of the addition of d-cycloserine to a program of brief exposure-based CBT for the treatment of panic disorder with or without agoraphobia. This study addresses an important public health issue by assessing an intervention that may help lead to a more efficient and effective application of empirically-based psychosocial interventions for the treatment of panic disorder and other anxiety disorders. This novel strategy of combining exposure-based treatment and d-cycloserine remains a particularly promising strategy among disappointing alternatives for the treatment of individuals with anxiety disorders, and our research will also provide valuable information on potential genetic moderators of both CBT efficacy as well as d-cycloserine enhancement of this efficacy.
描述(由申请人提供):这是一项3中心(PI:Drs. Otto、Pollack、Tolin)协作研究R 01。在这个应用程序中,我们建议进一步验证和扩展的转化研究的明显惊人的成功之一。具体而言,对恐惧消退背后的神经回路的基础研究导致对d-环丝氨酸(杏仁核中NMDA受体的部分激动剂)作为能够增强消退学习的药剂的检查(Davis等人,2006 a; Davis等人,2006年b)。在动物实验室中成功验证了这一策略后,Ressler等人(2004年)表明,在身高恐惧成年人的人类暴露范例中,单剂量的d-环丝氨酸(DCS)可增强灭绝。这一令人兴奋的初步发现被我们的研究小组复制,用于治疗门诊患者的社交焦虑障碍(Hofmann et al.,2006年),我们还完成了一项试点研究,表明对其他焦虑症的治疗也有类似的好处。正如安德森和Insel(2006)所讨论的,这些发现有可能促进焦虑症治疗的重大进展。目前的研究代表了DCS的进一步应用,以增强暴露为基础的认知行为疗法(CBT)的效果,现在应用于治疗惊恐障碍伴或不伴广场恐怖症。在本申请中,我们提出了一项双盲随机对照试验,在三个治疗地点进行,以比较与安慰剂相比,惊恐障碍患者使用DCS增强基于焦虑的CBT的相对获益。此外,通过研究特定基因位点的变异性作为治疗反应的预测因子,特别是对于DCS增强的影响,我们试图确定哪些患者可能对这种形式的简短联合治疗特别敏感。本研究利用最近在转化研究中取得的成功,研究了将d-环丝氨酸添加到基于短暂性焦虑的CBT治疗伴有或不伴有广场恐怖症的惊恐障碍的方案中的益处。本研究通过评估一种干预措施来解决一个重要的公共卫生问题,这种干预措施可能有助于更有效地应用基于精神病学的心理社会干预措施来治疗恐慌症和其他焦虑症。在治疗焦虑症患者的令人失望的替代方案中,这种基于暴露的治疗和d-环丝氨酸相结合的新策略仍然是一种特别有前途的策略,我们的研究还将提供有关CBT疗效和d-环丝氨酸的潜在遗传调节剂的宝贵信息。-环丝氨酸增强这种功效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARK H POLLACK其他文献

MARK H POLLACK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARK H POLLACK', 18)}}的其他基金

Dose Timing of D-cycloserine to Augment CBT for Social Anxiety Disorder
D-环丝氨酸增强 CBT 治疗社交焦虑症的剂量时机
  • 批准号:
    9124959
  • 财政年份:
    2014
  • 资助金额:
    $ 23.9万
  • 项目类别:
Dose Timing of D-cycloserine to Augment CBT for Social Anxiety Disorder
D-环丝氨酸增强 CBT 治疗社交焦虑症的剂量时机
  • 批准号:
    8911367
  • 财政年份:
    2014
  • 资助金额:
    $ 23.9万
  • 项目类别:
Dose Timing of D-cycloserine to Augment CBT for Social Anxiety Disorder
D-环丝氨酸增强 CBT 治疗社交焦虑症的剂量时机
  • 批准号:
    8700098
  • 财政年份:
    2014
  • 资助金额:
    $ 23.9万
  • 项目类别:
Eszopiclone for the Treatment of PTSD
右佐匹克隆治疗创伤后应激障碍 (PTSD)
  • 批准号:
    8488476
  • 财政年份:
    2011
  • 资助金额:
    $ 23.9万
  • 项目类别:
Eszopiclone for the Treatment of PTSD
右佐匹克隆治疗创伤后应激障碍 (PTSD)
  • 批准号:
    8317540
  • 财政年份:
    2011
  • 资助金额:
    $ 23.9万
  • 项目类别:
Eszopiclone for the Treatment of PTSD
右佐匹克隆治疗创伤后应激障碍 (PTSD)
  • 批准号:
    8112172
  • 财政年份:
    2011
  • 资助金额:
    $ 23.9万
  • 项目类别:
D-Cycloserine Enhancement of Exposure in Social Phobia
D-环丝氨酸增强社交恐惧症的暴露程度
  • 批准号:
    8030499
  • 财政年份:
    2010
  • 资助金额:
    $ 23.9万
  • 项目类别:
3/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder
恐慌症中的 3/3 暴露 D-环丝氨酸增强剂和遗传调节剂
  • 批准号:
    8279653
  • 财政年份:
    2008
  • 资助金额:
    $ 23.9万
  • 项目类别:
3/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder
恐慌症中的 3/3 暴露 D-环丝氨酸增强剂和遗传调节剂
  • 批准号:
    8051529
  • 财政年份:
    2008
  • 资助金额:
    $ 23.9万
  • 项目类别:
3/3-Exposure D-Cycloserine Enhancement and Genetic Modulators in Panic Disorder
恐慌症中的 3/3 暴露 D-环丝氨酸增强剂和遗传调节剂
  • 批准号:
    7616448
  • 财政年份:
    2008
  • 资助金额:
    $ 23.9万
  • 项目类别:

相似海外基金

Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
  • 批准号:
    2244994
  • 财政年份:
    2023
  • 资助金额:
    $ 23.9万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了